MEI Pharma Files 8-K: Regulation FD & Exhibits

Ticker: LITS · Form: 8-K · Filed: Jul 30, 2024 · CIK: 1262104

Mei Pharma, INC. 8-K Filing Summary
FieldDetail
CompanyMei Pharma, INC. (LITS)
Form Type8-K
Filed DateJul 30, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.00000002
Sentimentneutral

Sentiment: neutral

Topics: disclosure, regulatory

TL;DR

MEI Pharma filed a routine 8-K on July 30th for Reg FD and exhibits. No major news.

AI Summary

On July 30, 2024, MEI Pharma, Inc. filed an 8-K report to disclose information regarding a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form.

Why It Matters

This 8-K filing serves as a standard disclosure for MEI Pharma, Inc., informing the public about regulatory compliance and financial reporting without detailing new material events.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any new material risks or events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by MEI Pharma, Inc.?

The primary purpose of this 8-K filing is to report under Regulation FD Disclosure and to provide Financial Statements and Exhibits.

What is the exact date of the report for MEI Pharma, Inc.?

The exact date of the report for MEI Pharma, Inc. is July 30, 2024.

What is the principal executive office address for MEI Pharma, Inc.?

The principal executive office address for MEI Pharma, Inc. is 11455 El Camino Real, Suite 250, San Diego, California, 92130.

What is the IRS Employer Identification Number for MEI Pharma, Inc.?

The IRS Employer Identification Number for MEI Pharma, Inc. is 51-0407811.

Does this 8-K filing announce any new material events or financial results?

This 8-K filing is primarily for Regulation FD Disclosure and Financial Statements and Exhibits, and does not appear to announce specific new material events or detailed financial results within the provided text.

Filing Stats: 718 words · 3 min read · ~2 pages · Grade level 13.4 · Accepted 2024-07-30 16:05:21

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On July 22, 2024, MEI Pharma, Inc. (the "Company") announced that its Board of Directors had determined unanimously to begin an evaluation of the Company's strategic alternatives, including potential transactions as well as an orderly wind-down of the Company, if necessary, in order to maximize the value of its assets. The Company also announced that it intended to promptly discontinue the clinical development of voruciclib, while continuing to conduct certain non-clinical activities related to the Company's drug candidate assets. The Company intends to utilize presentation materials (the "Corporate Presentation") in substantially the form attached to this Current Report on Form 8-K as Exhibit 99.1 in connection with the activities described above. These materials primarily describe the status of the Company's voruciclib program. The information contained in the Corporate Presentation is summary information that should be considered in the context of the Company's filings with the Securities and Exchange Commission and other public announcements the Company may make by press release or otherwise from time to time. The Corporate Presentation speaks as of the date of this Current Report. While the Company may elect to update the Corporate Presentation in the future to reflect events and circumstances occurring or existing after the date of this Current Report, the Company specifically disclaims any obligation to do so. By furnishing this Current Report on Form 8-K and furnishing the Corporate Presentation, the Company makes no admission as to the materiality of any information in this Current Report, including without limitation the Corporate Presentation. The Corporate Presentation contains forward-looking statements. See Page 2 of the Corporate Presentation for a discussion of certain forward-looking statements that are included therein and the risks and uncertainties related thereto. The information set forth in this It

/01 Financial Statements and Exhibits

Item 9/01 Financial Statements and Exhibits No. Description 99.1 Corporate Presentation July 2024

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MEI Pharma, Inc. Date: July 30, 2024 By: Justin J. File Justin J. File Chief Financial Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing